Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines

References

• Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time [ published correction appears in Lancet Infect Dis2020 Sep;20(9):e215]. Lancet Infect Dis. 2020;20(5):533–7. doi:10.1016/S1473-3099(20)30120-1.
   PubMed Web of Science ®Google Scholar
• WHO. Status of COVID-19 vaccines within WHO EUL/PQ evaluation process. 2021 [accessed 2021 Oct 16].
   Google Scholar
• COVID-19 WHO Thailand Situation Reports. [accessed 2021 Oct 16]. https://cdn.who.int/media/docs/default-source/searo/thailand/2021_10_14_tha-sitrep-205-covid-19.pdf?sfvrsn=8ba57507_3
   Google Scholar
• Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, Pizarro A, Acevedo J, Leo K, Leon F, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):875–84. doi:10.1056/NEJMoa2107715.
   PubMed Web of Science ®Google Scholar
• Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. Jama. 2021;326(1):35–45. doi:10.1001/jama.2021.8565.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, et al.; . AstraZeneca AZD1222 Clinical Study Group. Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCov-19) Covid-19 vaccine. N Engl J Med. 2021;385(25):2348–60. doi:10.1056/NEJMoa2105290.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, De Serres G. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2021;384(16):1576–77. doi:10.1056/NEJMc2036242.
   PubMedGoogle Scholar
• Department of Disease Control MoPH. Thailand. a guide to COVID-19 vaccines in Thailand. 2021 [accessed 2021 Oct 16]. https://www.who.int/thailand/news/detail/08-07-2021-a-guide-to-covid-19-vaccines-in-thailand
   Google Scholar
• Fournillier A, Frelin L, Jacquier E, Ahlén G, Brass A, Gerossier E, Holmström F, Broderick KE, Sardesai NY, Bonnefoy J-Y, et al. A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. J Infect Dis. 2013;208(6):1008–19. doi:10.1093/infdis/jit267.
   PubMed Web of Science ®Google Scholar
• Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398(10303):856–69. doi:10.1016/S0140-6736(21)01694-9.
   PubMed Web of Science ®Google Scholar
• Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdox1 nCov-19/bnt162b2 vaccination. Nat Med. 2021;27(9):1525–29. doi:10.1038/s41591-021-01449-9.
   PubMed Web of Science ®Google Scholar
• Poon RW, Lu L, Fong CH, Ip TC, Chen LL, Zhang RR, Yip CC, Cheng VC, Chan KH, Yuen KY, et al. Correlation between commercial anti-RBD IgG titer and neutralization titer against SARS-CoV-2 beta variant. Diagnostics (Basel). 2021;11(12):2216. [accessed 2021 Nov 27]. doi:10.3390/diagnostics11122216.
   PubMedGoogle Scholar
• Morinaga Y, Tani H, Terasaki Y, Nomura S, Kawasuji H, Shimada T, Igarashi E, Saga Y, Yoshida Y, Yasukochi R, et al. Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants. Microbiol Spectr. 2021;9(3):e0056021. doi:10.1128/Spectrum.00560-21.
   PubMed Web of Science ®Google Scholar
• Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch I, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032–40. doi:10.1038/s41591-021-01540-1.
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, Plotkin S, Knezevic I. WHO international standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347–48. doi:10.1016/S0140-6736(21)00527-4.
   PubMed Web of Science ®Google Scholar
• Resman Rus K, Korva M, Knap N, Avšič Županc T, Poljak M. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay. J Clin Virol. 2021;139:104820. doi:10.1016/j.jcv.2021.104820.
   PubMed Web of Science ®Google Scholar
• Liu G, Rusling JF. COVID-19 antibody tests and their limitations. ACS Sens. 2021;6(3):593–612. doi:10.1021/acssensors.0c02621.
   PubMed Web of Science ®Google Scholar
• Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdox1 nCov-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study. Lancet Reg Health Eur. 2021;11:100249. doi:10.1016/j.lanepe.2021.100249.
   PubMedGoogle Scholar
• Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M, Peyrot L, Allatif O, Fassier JB, Massardier-Pilonchéry A, et al. Immunogenicity and efficacy of heterologous ChAdox1-BNT162b2 vaccination. Nature. 2021;600(7890):701–06. doi:10.1038/s41586-021-04120-y.
   PubMed Web of Science ®Google Scholar
• Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009;21(3):346–51. doi:10.1016/j.coi.2009.05.016.
   PubMed Web of Science ®Google Scholar
• Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585–94. doi:10.1056/NEJMoa2108891.
   PubMed Web of Science ®Google Scholar
• Stoel M, Pool J, de Vries-Idema J, Zaaraoui-Boutahar F, Bijl M, Andeweg AC, Wilschut J, Huckriede A. Innate responses induced by whole inactivated virus or subunit influenza vaccines in cultured dendritic cells correlate with immune responses in vivo. PLoS One. 2015;10(5):e0125228. accessed 2015 May 1. doi:10.1371/journal.pone.0125228.
   PubMed Web of Science ®Google Scholar
• Couture A, Garnier A, Docagne F, Boyer O, Vivien D, Le-Mauff B, Latouche JB, Toutirais O. HLA-Class II artificial antigen presenting cells in CD4+ T cell-based immunotherapy. Front Immunol. 2019 [accessed 2019 May 17];10:1081. doi:10.3389/fimmu.2019.01081.
   PubMed Web of Science ®Google Scholar
• Goyal K, Goel H, Baranwal P, Tewary A, Dixit A, Pandey AK, Benjamin M, Tanwar P, Dey A, Khan F, et al. Immunological mechanisms of vaccine-induced protection against SARS-CoV-2 in humans. Immuno. 2021;1(4):442–56. doi:10.3390/immuno1040032.
   Google Scholar
• Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21:475–84.
   PubMed Web of Science ®Google Scholar
• Sakurai F, Tachibana M, Mizuguchi H. Adenovirus vector-based vaccine for infectious diseases. Drug Metab Pharmacokinet. 2022;42:100432. doi:10.1016/j.dmpk.2021.100432.
   PubMed Web of Science ®Google Scholar
• Joffre OP, Segura E, Savina A, Amigorena S. Cross-Presentation by dendritic cells. Nat Rev Immunol. 2012 [ accessed 2012 Jul 13];12(8):557–69. doi:10.1038/nri3254.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Valdés I, Lazo L, Hermida L, Guillén G, Gil L. Can complementary prime-boost immunization strategies be an alternative and promising vaccine approach against dengue virus? Front Immunol. 2019 [accessed 2019 Aug 27];10:1956. doi:10.3389/fimmu.2019.01956.
   PubMed Web of Science ®Google Scholar
• Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Hsieh RH, Mestecky J, Zolla-Pazner S, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis. 1998;177(5):1230–46. doi:10.1086/515288.
   PubMed Web of Science ®Google Scholar
• Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Ledgerwood JE, Bailer RT, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One. 2010;5(2):e9015. [accessed 2010 Feb 2]. doi:10.1371/journal.pone.0009015.
   PubMed Web of Science ®Google Scholar
• Li M, Yang J, Wang L, Wu Q, Wu Z, Zheng W, Wang L, Lu W, Deng X, Peng C, et al. A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. doi:10.1101/2021.08.03.21261544.
   Google Scholar
• Liu Y, Zeng Q, Deng C, Li M, Li L, Liu D, Liu M, Ruan X, Mei J, Mo R, et al. Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine. Cell Discovery. 2022;8(1):10. [accessed 2022 Feb 1]. doi:10.1038/s41421-022-00373-7.
   PubMed Web of Science ®Google Scholar
• Shete A, Thakar M, Mehendale SM, Paranjape RS. Is prime boost strategy a promising approach in HIV vaccine development? J AIDS Clin Res. 5:293. doi:10.4172/2155-6113.1000293.
   Google Scholar
• Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity. 2010;33(4):451–63. doi:10.1016/j.immuni.2010.10.008.
   PubMed Web of Science ®Google Scholar
• Palgen JL, Feraoun Y, Dzangué-Tchoupou G, Joly C, Martinon F, Le Grand R, Beignon AS. Optimize prime/boost vaccine strategies: trained immunity as a new player in the game. Front Immunol. 2021 [accessed 2021 Mar 8];12:612747. doi:10.3389/fimmu.2021.612747.
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Single-Dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdox1 nCov-19 (AZD1222) vaccine: a pooled analysis of four randomised trials [published correction appears in Lancet. 2021 Mar 6;397(10277):880]. Lancet. 2021;397(10277):881–91. doi:10.1016/S0140-6736(21)00432-3.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia [published correction appears in Lancet. 2021 Feb 20;397(10275):670]. Lancet. 2021;397(10275):671–81. doi:10.1016/S0140-6736(21)00234-8.
   PubMed Web of Science ®Google Scholar
• Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, Wu Z, Jiang D, Deng X, Chu K, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials [published online ahead of print, 2021 Dec 7]. Lancet Infect Dis. 2021;S1473-3099(21):00681–2. doi:10.1016/S1473-3099(21)00681-2.
   Google Scholar